J. Gross
Northwestern University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by J. Gross.
American Journal of Clinical Oncology | 2017
Tamer Refaat; Eric D. Donnelly; Sean Sachdev; Vamsi Parimi; Samar El Achy; Prarthana Dalal; Mohamed Farouk; Natasha Berg; Irene B. Helenowski; J. Gross; John R. Lurain; Jonathan B. Strauss; Gayle E. Woloschak; Jian Jun Wei; William Small
Purpose: This study aimed to assess the association between pretreatment c-Met overexpression in local-regional advanced cervical cancer patients treated definitively with concurrent chemoradiation therapy (CRT) and treatment outcomes including overall survival (OS), progression-free survival (PFS), distant metastases (DM) control, and local-regional control (LC). Patients and Methods: This Institutional Review Board–approved study included cervical cancer patients treated definitively and consecutively with CRT. Evaluation of cytoplasmic immunoreactivity for c-Met was performed and scored semiquantitatively by 3 pathologists, blinded to the treatment outcomes, and incorporated both the intensity and percentage of immunoreactivity in invasive carcinoma (H score). Treatment outcomes were reviewed and reported. Outcomes were stratified by c-Met overexpression and tumor characteristics. OS, PFS, LC, and DC rates were obtained via the Kaplan-Meier method and differences between groups were evaluated by the log-rank test. Hazard ratios were obtained via Cox regression for both univariate and multivariate analyses. Results: The 5-year OS, PFS, LC, and DC were 57.18%, 48.07%, 72.11%, and 62.85%, respectively. Ten (35.7%) and 18 patients (64.3%) had c-Met H index >30 and<30, respectively. c-Met overexpression was significantly associated with worse 3- and 5-year OS (P=0.003), PFS (P=0.002), LC (P=0.01), and DC (P=0.0003). Patients with c-Met overexpression had a hazard ratio of 6.297, 5.782, 6.28, and 18.173 for the risks of death, disease progression, local recurrence, and DM, respectively. Conclusion: c-Met overexpression could be a potential predictive marker and therapeutic target for local-regional advanced cervical cancer patients treated definitively with CRT.
Journal of Clinical Oncology | 2017
J. Gross; Tim J. Kruser
International Journal of Radiation Oncology Biology Physics | 2015
Tamer Refaat; Eric D. Donnelly; Sean Sachdev; Vamsi Parimi; S. El Achy; Prarthana Dalal; Mohamed Farouk; K.N. Berg; I. Helenowksi; J. Gross; John R. Lurain; Jonathan B. Strauss; Gayle E. Woloschak; Jian Jun Wei; William Small
Neuro-oncology | 2018
J. Gross; Stephanie Powell; Frank Zelko; W.F. Hartsell; Stewart Goldman; Jason Fangusaro; Rishi Lulla; Natasha Pillay-Smiley; John Chang; Vinai Gondi
Journal of Clinical Oncology | 2018
Tim J. Kruser; Jacqueline M. Kruser; J. Gross; Margaret R. Moran; Karen Kaiser; Eytan Szmuilowicz; Sheetal Mehta Kircher
International Journal of Radiation Oncology Biology Physics | 2018
J. Gross; Eric D. Donnelly; Jonathan B. Strauss
International Journal of Radiation Oncology Biology Physics | 2018
J. Gross; Sean Sachdev; Irene B. Helenowski; David B. Lipps; John P. Hayes; Eric D. Donnelly; Jonathan B. Strauss
Journal of Clinical Oncology | 2017
Prarthana Dalal; Tamer Refaat; Eric D. Donnelly; Sean Sachdev; Vamsi Parimi; Samar Elachy; Ahmed Elgowily; Irene B. Helenowski; J. Gross; John R. Lurain; Jonathan B. Strauss; Gayle E. Woloschak; Jian Jun Wei; William Small
International Journal of Radiation Oncology Biology Physics | 2017
J. Gross; Sean Sachdev; David B. Lipps; Eric D. Donnelly; John P. Hayes; Jonathan B. Strauss
Journal of Radiation Oncology | 2016
J. Gross; Jonathan B. Strauss; John R. Lurain; Emily Berry; Nikki L. Neubauer; Irene B. Helenowski; Eric D. Donnelly